Organic compounds and their uses

1. A compound of the Formula I:

and pharmaceutically acceptable salts and stereoisomers thereof;

wherein

y is 0 or 1;

n and p are each independently 0, 1 or 2;

R 14 is C(O) or SO 2 ;

R 1 , R 2 , W, R 13 and V are each, independently, selected from hydrogen or from the group consisting of alkyl, alkyl-aryl, heteroalkyl, heterocyclyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyloxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocyclyloxy, cycloalkyloxy, amino, alkylamino, arylamino, alkyl-arylamino, arylamino, heteroarylamino, cycloalkylamino, carboxyalkylamino, mono- and di-alkylcarboxamide, aralkyloxy and heterocyclylamino; each of which may be further independently substituted one or more times with X 1 and X 2 ; wherein X 1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, aralkyl, aryloxy, arylthio, arylheteroaryl, heteroaryl, heterocyclylamino, alkylheteroaryl, or heteroaralkyl; wherein X 1 can be independently substituted with one or more X 2 moieties which can be the same or different and are independently selected; wherein X 2 is hydroxy, oxo, alkyl, cycloalkyl, spirocycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, thio, alkylthio, amino, mono- and di-alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyl, alkoxycarbonyloxy, alkylureido, arylureido, halogen, cyano, or nitro; wherein each X 2 residue selected to be alkyl, alkoxy, and aryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different and are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, aralkyl, arylheteroaryl, heteroaryl, heterocyclylamino, alkylheteroaryl and heteroaralkyl;

W is also selected from the group consisting of C(O)—C(O)H, C(═N—O—R 24 )—C(O)-amine, C(O)—C(O)-amine, C(O)NR 24 S(O) p R 24 , C(O)NR 24 S(O) p N(R 24 ) 2 and C(O)—[C(O)] a -heterocycle, wherein the heterocycle may be independently substituted one or more times with aryl, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, and C 3-6 -cycloalkyl, wherein a is 0 or 1, wherein each R 24 is independently selected from hydrogen or the group consisting of C 1-4 -alkyl, C 3-6 -cycloalkylC 0-4 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle, each of which may be independently substituted one or more times with a halogen atom or C 1-4 -alkyl;

V is also selected from the group consisting of -Q 1 -Q 2 , wherein Q 1 is absent, C(O), N(H), N(C 1-4 -alkyl), C═N(CN), C═N(SO 2 CH 3 ), C═N—COH—C 1-4 -alkyl, or C═N—COH, and Q 2 is hydrogen or is selected from the group consisting of C 1-4 -alkyl, O—C 1-4 -alkyl, NH 2 , N(H)—C 1-4 -alkyl, N(C 1-4 -alkyl) 2 , SO 2 -aryl, SO 2 -C 1-4 -alkyl, C 3-6 -cycloalkyl-C 0-4 -alkyl, aryl, heteroaryl and heterocycle, each of which may be independently substituted one or more times with a halogen atom, C 1-4 - alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, or C 3-6 -cycloalkyl;

or R 1 and R 2 may together form a 3, 4, 5, 6 or 7-membered ring that is aromatic or non-aromatic and may contain one or more heteroatoms, wherein the ring may be further substituted one or more times;

R 3 is selected from the group consisting of hydrogen, C 1-4 -alkyl and C 3-6 cycloalkylC 0-4 alkyl;

the divalent residue:

 is selected from the group consisting of:

R 8 , R 9 , R 10 , R 11 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-4 -alkyl and C 3-6 cycloalkylC 0-4 alkyl;

or R 3 and W may together form a 3, 4, 5, 6 or 7-membered ring that is aromatic or non-aromatic and may contain one or more heteroatoms, wherein the ring may be further substituted one or more times; and

or when y is 0, R 10 and V may together form a 3, 4, 5, 6 or 7-membered ring that is aromatic or non-aromatic and may contain one or more heteroatoms, wherein the ring may be further substituted one or more times.

2. The compound of claim 1 ,

wherein

y is 0 or 1;

n is 0 or 1;

R 14 is C(O) or SO 2

R 1 is selected from the group consisting of H and C 1-4 -alkyl;

R 2 is selected from the group consisting of C 1-4 -alkyl, C(O)C 1-4 -alkyl, C(O)OC 1-4 -alkyl, and C 3-6 cycloalkylC 0-4 alkyl;

or R 1 and R 2 together form a cyclopropane ring;

W is selected from the group consisting of C(O)—C(O)H, C(═N—O—R 24 )—C(O)-amine, C(O)—C(O)-amine, C(O)NR 24 S(O) p R 24 , C(O)NR 24 S(O) p N(R 24 ) 2 and C(O)—[C(O)] a -heterocycle, wherein the heterocycle may be independently substituted one or more times with aryl, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, and C 3-6 -cycloalkyl, wherein a is 0 or 1, wherein each R 24 is independently selected from hydrogen or from the group consisting of C 1-4 -alkyl, C 3-6 cycloalkylC 0-4 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle, each of which may be independently substituted one or more times with a halogen atom or C 1-4 -alkyl;

p is 0, 1 or 2;

R 3 is selected from the group consisting of H and C 1-4 -alkyl;

R 13 is H;

R 9 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-4 -alkyl and C 3-6 -cycloalkyl; and

V is selected from the group consisting of -Q 1 -Q 2 , wherein Q 1 is absent, C(O), N(H), N(C 1-4 -alkyl), C═N(CN), C═N(SO 2 CH 3 ), C═N—COH—C 1-4 -alkyl, or C═N—COH, and Q 2 is hydrogen or is selected from the group consisting of C 1-4 -alkyl, O—C 1-4 -alkyl, NH 2 , N(H)—C 1-4 -alkyl, N(C 1-4 -alkyl) 2 , SO 2 -aryl, SO 2 —C 1-4 -alkyl, C 3-6 -cycloalkyl-C 0- 4 -alkyl, aryl, heteroaryl and heterocycle, each of which may be independently substituted one or more times with a halogen atom, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, or C 3-6 -cycloalkyl;

or R 3 and W can together form a 6-membered ring of the formula II:

wherein formula II may be further substituted;

or when y is 0, R 10 and V can form a cyclopropyl ring that may be further substituted by an amide group.

3. The compound of claim 1 , wherein R 14 is C(O).

4. The compound of claim 1 , wherein y is 0, and R 10 and V form a cyclopropyl ring that is substituted with C(O)N(H)-pyrazine.

5. The compound of claim 1 , wherein R 1 and R 2 , are independently selected from hydrogen or from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkylC 0-4 alkyl, C 3-6 cycloalkenylC 0-4 alkyl, C 1-4 alkoxyC 0-4 alkyl, and heterocycloalkylC 0-4 alkyl, each of which is unsubstituted or substituted with one or more groups selected from fluoro, chloro, hydroxy, C 1-2 alkylS, C 1-2 alkylS(O), and C 1-2 alkylS(O) 2 , and wherein the heterocycloalkyl is a 3 to 6 membered ring having one or two N, O or S ring atoms.

6. The compound of claim 1 , wherein R 1 is hydrogen and R 2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, allyl, propargyl, 3-fluoro-n-propyl, n-butyl, n-pentyl, iso-propyl, sec-butyl, iso-butyl, 3-methyl-n-butyl, 3,3,3-trifluoro-n-propyl, 2,2-difluoroethyl, trifluoromethyl, 1,1-difluoro-n-propyl, 2,2,2-trifluoroethyl, 2,2-difluoro-n-but-3-enyl, 4-pentenyl, 3,3-difluoro-allyl, 2-methyl-allyl, 3-butenyl, 2-cyanoethyl, 3,3-difluoropropyl, 2,2-difluoro-3-butenyl, 2,2-difluoro-n-propyl, 4,4,4-trifluorobutyl, C 3-6 cycloalkyl, oxetan-2-ylmethyl, thietan-2-ylmethyl, 3-fluorocyclobutylmethyl, 3-hydroxycyclobutylmethyl, 3-butynyl, methoxymethyl, 2-methoxyethyl, methyl-S(O) 0-2 C 1-2 alkyl, 3,3-difluorocyclobutylmethyl, oxetan-3-ylmethyl, C 3-6 cycloalkylmethyl, 1-methylcyclopropylmethyl, C 3-6 cycloalkyl-difluoromethyl, C 3-6 cycloalkylethyl, thietan-3-ylmethyl, 1-fluorocyclobutylmethyl, 1-fluorocyclopropylmethyl, 2,2-difluorocyclopropylmethyl, and cyclopenten-2-ylmethyl.

7. The compound of claim 1 , wherein W is selected from the group consisting of C(O)—C(O)NH 2 , C(O)—C(O)N(H)-cyclopropyl, C(O)-benzothiazole, C(O)-benzoimidazole, C(O)-oxazole, C(O)-imidazole, and C(O)-oxadiazole, wherein the benzothiazole, benzoimidazole, oxazole and oxadiazole groups may be independently substituted one or more times with a halogen atom, aryl, trihalomethyl, C 3-6 -cycloalkyl or C 1-4 -alkyl.

8. The compound of claim 7 , wherein W is selected from the group consisting of

wherein R 19 is selected from the group consisting of hydrogen, aryl, trihalomethyl, and C 1-4 -alkyl.

9. The compound of claim 1 , wherein R 2 is selected from the group consisting of propyl and (CH 2 ) 2 -cyclobutyl.

10. The compound of claim 1 , wherein R 11 is H and R 12 is C 3-6 -cycloalkyl.

11. The compound of claim 1 , wherein V is R ° or C(O)-R 20 , wherein R 20 is selected from the group consisting of C 3-6 -cycloalkyl, mono- and di-C 1-4 alkylamino, phenyl, pyrazine, benzooxazole, 4,4-dimethyl-4,5-dihydro-oxazole, benzoimidazole, pyrimidine, benzothiazole 1,1-dioxide and quinazoline, each of which may be further independently substituted with a halogen atom, CF 3 , C 1-4 -alkyl or C 3-6 -cycloalkyl.

12. The compound of claim 1 , wherein V is selected from R ° or C(O)R 20 , wherein R ° is selected from the group consisting of

wherein b is 0, 1, or 2; and R 18 is selected from the group consisting of hydrogen, a halogen atom, aryl, trihalomethyl, and C 1-4 -alkyl.

13. The compound of claim 1 , wherein W is selected from the group consisting of C(O)—C(O)N(R 23 ) 2 , wherein R 23 is independently selected from hydrogen or from the group consisting of C 1-4 -alkyl, C 3-6 -cycloalkylC 0-4 alkyl, aryl and heterocycle, each of which may be independently substituted one or more times with a halogen atom or C 1-4 -alkyl.

14. A method of treating HCV infection, liver cirrhosis, chronic liver disease, cryoglobulinaemia, and/or a suppressed innate intracellular immune response in a subject in need thereof comprising administering to the subject a pharmaceutically acceptable amount of a compound of claim 1 .

15. A pharmaceutical composition, comprising:

a therapeutically effective amount of the compound of claim 1 and

a pharmaceutically acceptable excipient.